Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ombrabulin
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ombrabulin is a synthetic small molecule analogue of combretastatin A4, acting as a vascular disrupting agent (VDA) and antineoplastic. It inhibits tubulin polymerization by binding to the colchicine site of tubulin, leading to destabilization of the cytoskeleton in endothelial cells, causing rapid reduction in tumor blood flow and subsequent tumor necrosis. It was discovered by Ajinomoto and further developed by Sanofi-Aventis for cancer treatment, including solid tumors and soft tissue sarcoma. Development was discontinued after disappointing results in phase III clinical trials.
- Other names
- ombrabulin hydrochloride
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Ombrabulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ombrabulin.